
Palatin Technologies PTN
$ 19.64
-4.89%
Quarterly report 2025-Q4
added 02-17-2026
Palatin Technologies Cash Conversion Cycle 2011-2026 | PTN
Annual Cash Conversion Cycle Palatin Technologies
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 119 | -2.44 K | 418 | -1.77 K | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 418 | -2.44 K | -917 |
Quarterly Cash Conversion Cycle Palatin Technologies
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.49 K | - | - | - | - | - | - | - | -1.72 K | 92.4 | - | 134 | 170 | -2.71 K | 61.8 | -150 | 2.19 K | 1.45 K | 872 | 7.68 K | 12.3 K | 6.64 K | -1.2 K | -18.7 | 477 | 28.3 K | 267 K | 28.2 K | - | 136 | - | - | 40.4 K | 41.5 K | 130 | 25.6 | - | - | - | - | - | - | - | - | 17.3 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 267 K | -2.71 K | 17.4 K |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Verastem
VSTM
|
38.5 | $ 5.04 | -4.73 % | $ 349 M | ||
|
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | ||
|
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | ||
|
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | ||
|
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M | ||
|
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | ||
|
bluebird bio
BLUE
|
-54.4 | - | - | $ 546 M | ||
|
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
Avid Bioservices
CDMO
|
85.5 | - | - | $ 789 M | ||
|
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
72.3 | $ 12.41 | -11.1 % | $ 1.88 B | ||
|
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B | ||
|
BioDelivery Sciences International
BDSI
|
340 | - | -4.8 % | $ 255 M | ||
|
Cara Therapeutics
CARA
|
52.4 | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
3.1 | - | - | $ 3.74 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
-193 | $ 1.05 | -3.67 % | $ 21.5 M | ||
|
Summit Therapeutics
SMMT
|
379 | $ 16.58 | -3.94 % | $ 12.4 B | ||
|
Zymeworks
ZYME
|
211 | $ 24.18 | -2.07 % | $ 1.25 B | ||
|
AbbVie
ABBV
|
284 | $ 209.4 | -0.83 % | $ 370 B | ||
|
AbCellera Biologics
ABCL
|
173 | $ 3.27 | -2.39 % | $ 977 M | ||
|
Altimmune
ALT
|
7.85 K | $ 3.02 | -5.63 % | $ 266 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
46.6 | $ 317.36 | -3.29 % | $ 41.6 B | ||
|
Aytu BioScience
AYTU
|
174 | $ 2.6 | -2.8 % | $ 16.3 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
50 | $ 4.29 | -3.6 % | $ 822 M |